← Back to Home

India’s PopVax launches personalized cancer vaccine manufacturing service; efficacy in humans remains unproven

From tumor sequencing to mRNA vaccine production, RNA Foundry offers a service model costing approximately US$300,000 per project and taking 8 to 10 weeks. Manufacturing capacity is becoming available, but whether patients can benefit must still be answered by independent cancer vaccine clinical trials.

By SURL BioNews

Bringing personalized cancer vaccines to patients requires more than identifying a tumor’s vulnerabilities: each person’s distinct design must also be manufactured into a drug with controlled quality. PopVax, a biotechnology company based in Hyderabad, India, has partnered with Stochastic Sciences to launch RNA Foundry, offering services spanning design through manufacturing. However, what is being made available is experimental vaccine research, development, and production capacity; there is not yet evidence of the company’s cancer vaccines’ efficacy in humans.

According to RNA Foundry’s published service details, the team can accept externally designed mRNA sequences or design vaccine candidates using patients’ tumor sequencing data. The company estimates that most projects will cost approximately US$300,000 and require 8 to 10 weeks for production, with actual timelines depending on production line availability. Estimated capacity over the next 12 months exceeds 100 personalized vaccines. These figures describe the scale of the manufacturing service, not the number of people who have completed treatment.

The concept behind these vaccines is to select antigens arising from genetic mutations in tumors that may be recognized by the immune system, then use mRNA to carry instructions for producing those antigens. PopVax says its design process combines AI models with tools that predict antigen presentation and immunogenicity, after which the mRNA is encapsulated in lipid nanoparticles. These predictions help screen candidate targets; whether they can elicit a sufficient and effective antitumor response in humans still requires validation through experimental and clinical data.

After manufacturing, the team will test RNA identity and integrity, particle size, encapsulation efficiency, sterility, and endotoxins, among other parameters, and provide analytical and manufacturing records. However, quality testing determines whether a product meets predefined specifications; it cannot establish whether a vaccine can control tumors or extend patients’ lives.

The threshold for clinical use has also yet to be crossed. When The New Indian Express reported on November 2, these cancer vaccine candidates had not yet been administered to patients. At the time, the company planned to first seek opportunities for use outside India through pathways such as named-patient or compassionate use, subject to the relevant approvals. Founder Soham Sankaran subsequently told ThePrint that patients, physicians, and regulators in the country concerned would decide whether to administer the vaccines, and that the company expected to launch cancer vaccine trials within one to two years.

PopVax previously used the same mRNA and lipid nanoparticle platform to manufacture a COVID-19 vaccine candidate and advance it into clinical trials in Australia, but separate evidence of safety and efficacy is still needed for cancer applications. Sankaran also emphasized that personalized cancer vaccines are intended to complement existing therapies, rather than replace current treatment; tumor characteristics, disease stage, and prior treatments may all affect outcomes.

RNA Foundry makes personalized vaccine manufacturing services more concrete, while also laying out the costs and waiting times for patients. The approximately US$300,000 price per project means early access remains very limited. For this initiative, the next key question is not just whether vaccines can be delivered on time, but whether clinical trials can demonstrate that these individualized designs provide measurable medical benefits.

References

  1. CNBCTV18
  2. PopVax and Stochastic Sciences
  3. The New Indian Express
  4. ThePrint